bibliographic resource 2502645 [br/2502645]
https://w3id.org/oc/corpus/br/2502645

is a
title
  • Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study
publication date
  • 2009-01-01
contributor
format
identifier
part of